

Stellingen

1. The level of public awareness of pharmacogenomics and its impact upon society is often rather low. *This thesis*
2. A large proportion of physicians and pharmacists disagreed with the idea of direct-to-consumer genetic testing. *This thesis*
3. More than half of the key stakeholders are highly supportive of pharmacogenomics in Greece. *This thesis*
4. Genotype-guided warfarin therapy appears to be cost-effective for elderly patients in Croatia. *This thesis*
5. Genome-guided clopidogrel treatment may represent a cost-saving option for the management of myocardial infarction in Serbian patients. *This thesis*
6. Incremental cost-effectiveness ratio (ICER) is a tool used for cost-effectiveness analysis and is given by the difference in costs between two healthcare programs divided by the difference in outcomes between a new health care program and the existing approach. *Gafni et al. Soc Sci Med. 2006;62:2091-2100.*
7. Cost-minimization analysis is difficult to justify if two alternatives offer the same level of effectiveness. *Briggs and O'Brien. Health Econ. 2001;10:179-184.*
8. Cost-utility analysis uses various indices and tools to measure the quality of the patient's life, in order to adjust the result according to patient quality of life. *Torrance GW. J Health Econ. 1986;5:1-30*
9. The desired value for the willingness-to-pay indicator is approximately three times the average per capita income of the country. *Eichler et al. Value Health. 2004;7:518-528.*
10. Abacavir was among the very first cases for the application of economic analysis of genome-guided treatment interventions. *Hughes et al. Pharmacogenetics. 2004;14:335-342.*
11. "Not everything that counts can be counted, and not everything that can be counted, counts" Albert Einstein